You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

119 search results for: symposium

IL-4 and IL-13: Shared and Unique Roles in Atopic Dermatitis (AD) and Prurigo Nodularis (PN)
expert video

IL-4 and IL-13: Shared and Unique Roles in Atopic Dermatitis (AD) and Prurigo Nodularis (PN)

Dermatology
Highlights from the WCD 2023 ADVENT symposium, exploring the distinctions and shared elements of atopic dermatitis and prurigo nodularis.
View more
Practical Considerations for the Management of Children With Moderate-to-severe Atopic Dermatitis
expert video

Practical Considerations for the Management of Children With Moderate-to-severe Atopic Dermatitis

Dermatology
Highlights from the 2023 WCD ADVENT symposium, exploring practical considerations for the management of atopic dermatitis in children.
View more
Importance of Barrier Dysfunction in Driving AD Pathophysiology
expert video

Importance of Barrier Dysfunction in Driving AD Pathophysiology

Dermatology
The impact of type 2 inflammation on components of the skin barrier driving atopic dermatitis – a presentation from the ADVENT symposium at ISID 2023.
View more
Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis
expert video

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis

Dermatology
Presentations from the ADVENT symposium at the ISID 2023 meeting on the skin barrier, neuroimmune axis, and type 2 inflammation in atopic dermatitis.
View more
Immune System, Microbiome and Neuroimmune Crosstalk in the Skin: Implications for AD
expert video

Immune System, Microbiome and Neuroimmune Crosstalk in the Skin: Implications for AD

Dermatology
The role of dysbiosis in the propagation of type 2 inflammation and itch in atopic dermatitis – a presentation from the ADVENT symposium at ISID 2023.
View more
Targeting Type 2 Inflammation in Children with AD​
expert video

Targeting Type 2 Inflammation in Children with AD​

Dermatology
The impact of type 2 inflammation in itch and barrier dysfunction in atopic dermatitis – Presentation from the ADVENT symposium at EAACI 2023.
View more
EAACI 2023 | What is New in the Treatment of Children
expert video

EAACI 2023 | What is New in the Treatment of Children

Dermatology
Clinical trial and real-world data for targeted therapies for children with atopic dermatitis – Presentation from the ADVENT symposium at EAACI 2023.
View more
New Perspectives in Understanding the Pathophysiology of Atopic Dermatitis in Children
expert video

New Perspectives in Understanding the Pathophysiology of Atopic Dermatitis in Children

Dermatology
Highlights from the ADVENT WCD 2023 symposium delving into the pathophysiology and management of atopic dermatitis in children.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: GreeceChange country/region